Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19

Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19

Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data regarding their impact in fully vaccinated vulnerable subjects with mild-to-moderate COVID-19 are still limited, particularly in the...

Full description

Bibliographic Details
Main Authors: Giuseppe Bruno, Massimo Giotta, Serena Perelli, Giuseppina De Vita, Nicola Bartolomeo, Giovanni Battista Buccoliero
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Viruses
Subjects:
COVID-19
antivirals
SARS-CoV-2
Molnupiravir
Nirmatrelvir
Online Access:https://www.mdpi.com/1999-4915/14/11/2514

Internet

https://www.mdpi.com/1999-4915/14/11/2514

Similar Items